Drug companies that manufacture ketamine are expected to lead profits in the category, according to an Anesthesia Drug Market study. Ketalar, distributed by JHP Pharmaceuticals, is currently the only branded version of the drug offered on the market.
Ketalar is expected to maintain a high profile in the market over the next five years, according to the study, but could see a drop in sales due to an increasing demand for less expensive generic counterparts.
Related Articles on Anesthesiology:
Two Anesthesiologists Selected to Lead St. Joseph Medical Center Anesthesia Department
Anesthesiologist Receives American Pain Society Award
Anesthesiologist Elected to Massachusetts Medical Society House of Delegates
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
